156 results
10-K
2023 FY
EX-31.2
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
of setrusumab, alvelestat and etigilimab. We cannot give any assurance that any of these product candidates will receive regulatory approval, which … the market price of our ADSs to decline.
We depend heavily on the success of setrusumab, alvelestat and etigilimab. We cannot give any assurance
10-K
2023 FY
EX-31.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
27 Mar 24
Mereo BioPharma Reports Full Year 2023 Financial Results and Provides Corporate Update
4:08pm
statements are reasonable as and when made, there can be no assurance that future developments affecting the Company will be those that it anticipates
8-K
EX-99.1
MREO
Mereo Biopharma Group Plc
8 Jan 24
Mereo BioPharma Provides Update on Pipeline Progress and Corporate Developments
7:08am
effect on the Company. While management believes that these forward-looking statements are reasonable as and when made, there can be no assurance
6-K
EX-99.1
stw2y 8116yl5
23 Oct 23
Mereo BioPharma Reports on Recent Program Developments and Provides Financial Update
4:08pm
6-K
m3w p5kb73mq9d6q
17 Oct 23
Current report (foreign)
7:01am
6-K
EX-99.1
evm9p
17 Oct 23
Current report (foreign)
7:01am
6-K
EX-99.3
bekfh
7 Sep 23
Current report (foreign)
7:37am
6-K
EX-99.1
8j11rn59dzq nwm
5 Jun 23
Ultragenyx and Mereo BioPharma Announce Positive Data from the Ongoing Phase 2/3 Orbit
4:37pm
6-K
EX-99.1
k2tue3l 85m9is7
8 May 23
Current report (foreign)
4:07pm
6-K
EX-99.1
gm1ps
5 May 23
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
5:06pm
6-K
c0jtfhw6
27 Apr 23
Current report (foreign)
4:15pm
6-K
9ro6y7
10 Nov 22
Current report (foreign)
4:10pm
6-K
EX-99.1
ebsmpi
2 Nov 22
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency
4:07pm
6-K
EX-99.2
32bj3ig8ljkbgpaj40
28 Oct 22
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
7:11am
6-K
EX-99.1
j1koqfs2q nq6xem
28 Oct 22
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
7:11am
6-K
EX-99.1
m53sp 8hxa3lv7wk
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.1
11nk1qkuiut5ste5
18 Oct 22
Mereo BioPharma Announces Updated Operating Plan to Maximize Shareholder Value
7:07am
6-K
EX-99.1
q5a 7hrvyr62z8
17 Oct 22
Mereo BioPharma Receives FDA Fast Track Designation for Alvelestat for Treatment of
7:16am